Sandoz gets green light from US FDA for high strength Humira biosimilar 23-Mar-2023 By Jane Byrne Sandoz intends to launch Hyrimoz citrate-free HCF in the US on July 1, 2023.
FDA reviewing higher dose Hyrimoz biosimilar 21-Jul-2022 By Jane Byrne The US FDA has accepted a supplemental biologics license application (sBLA) from Sandoz for a high concentration formulation of 100 mg/mL (HCF) of its biosimilar, Hyrimoz.
